Shanghai Huanhua Pharmaceutical

Shanghai Huanhua Pharmaceutical is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics for autoimmune diseases and oncology. Based in Shanghai, the company focuses on high-value targets with validated biology, such as TYK2 and TLR7/8, to create best-in-class or first-in-class treatments. Its lead program, HH-018, is a highly selective TYK2 inhibitor currently undergoing Phase 2 clinical trials for the treatment of moderate-to-severe plaque psoriasis. Additionally, the company is advancing HH-003, a dual TLR7/8 agonist, into clinical studies for solid tumors. Huanhua is supported by prominent venture capital firms and led by an experienced management team with deep expertise in drug discovery and development.